Importantly, our analysis of the clinical database further suggested that CES1 levels tended to have a negative association with the survival rate of sorafenib-treated HCC, suggesting that targeting CES1 might have the potential to sensitize HCC to a broad range of chemotherapeutic agents. Here, CES1 is linked to hepatocellular carcinoma.